Drug Profile
Research programme: MAP3K8 protein inhibitors - Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Indazoles; Naphthyridines; Quinolines; Small molecules
- Mechanism of Action MAP3K8 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
- 01 Sep 2011 Preclinical development is ongoing in USA
- 15 Oct 2009 Wyeth has been acquired by Pfizer